EPISODE · Apr 26, 2024 · 3 MIN
FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors.
Embed this episode
Ready to play
FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors
0:00
3:30
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?
This episode is 3 minutes long.
When was this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode published?
This episode was published on April 26, 2024.
Can I download this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!